Event Title

Synthesis of BRL-37959 and Analogues

Mentor 1

Dr. Hossain

Location

Union Wisconsin Room

Start Date

29-4-2016 1:30 PM

End Date

29-4-2016 3:30 PM

Description

The replacement of opiates for post operational pain is a necessity in modern medicine, opiate based drugs have many problems: addiction and gastric irritancy are two of the main complications that arise from their use. BRL 37959 is a compound, which was first synthesized in 1986 and was shown to have great promise as a pain killer, being classified as a non-steroidal anti-inflammatory drug, which work by inhibiting the COX enzyme. A study performed in 2004 has shown that the over expression of the COX enzyme is also linked to several types of cancer, making this compound a likely candidate for cancer therapy. The original synthesis of BRL-37959 was extremely inefficient, particularly during the formation of the benzofuran backbone, causing the compound not to be further studied. In 2006, the Hossain lab approached the synthesis of BRL-37959 after developing a reaction which formed benzofuran rings in high yield. My main goal of this study was to synthesize BRL-37959 and various analogs in the most efficient and greenest way possible. We have now completed the synthesis of the main compound using a new catalyst and microwave reactions, improving one step from a 10% to a 70% yield, giving a 60-70% yield over the course of the synthesis. The compound, and several more analogs are now being prepared in greater quantities and more quickly. These compounds will be sent to a collaborator at Vanderbilt University for COX inhibition testing, as well as the biology department here at the University of Milwaukee for screening against cancer cell lines.

This document is currently not available here.

Share

COinS
 
Apr 29th, 1:30 PM Apr 29th, 3:30 PM

Synthesis of BRL-37959 and Analogues

Union Wisconsin Room

The replacement of opiates for post operational pain is a necessity in modern medicine, opiate based drugs have many problems: addiction and gastric irritancy are two of the main complications that arise from their use. BRL 37959 is a compound, which was first synthesized in 1986 and was shown to have great promise as a pain killer, being classified as a non-steroidal anti-inflammatory drug, which work by inhibiting the COX enzyme. A study performed in 2004 has shown that the over expression of the COX enzyme is also linked to several types of cancer, making this compound a likely candidate for cancer therapy. The original synthesis of BRL-37959 was extremely inefficient, particularly during the formation of the benzofuran backbone, causing the compound not to be further studied. In 2006, the Hossain lab approached the synthesis of BRL-37959 after developing a reaction which formed benzofuran rings in high yield. My main goal of this study was to synthesize BRL-37959 and various analogs in the most efficient and greenest way possible. We have now completed the synthesis of the main compound using a new catalyst and microwave reactions, improving one step from a 10% to a 70% yield, giving a 60-70% yield over the course of the synthesis. The compound, and several more analogs are now being prepared in greater quantities and more quickly. These compounds will be sent to a collaborator at Vanderbilt University for COX inhibition testing, as well as the biology department here at the University of Milwaukee for screening against cancer cell lines.